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The cardiovascular development is the elaborate process, and despite the extensive studies, the mechanisms underlying endothelial,
hematopoietic, and cardiac developments, as well as the interrelation between these processes, are not fully understood. In this study, we
demonstrated that Xenopus apelin and Xmsr play pivotal roles in cardiovascular development. Apelin is a recently identified ligand for an orphan
G-protein-coupled receptor APJ and is involved in fluid homeostasis in mammals. Xenopus preproapelin (Xpreproapelin) was isolated and its
mRNA localized to the region around the presumptive blood vessels, which are overlapping or adjacent to those expressing Xmsr, the Xenopus
homologue of APJ. Overexpression of Xpreproapelin disorganized the expression of the endothelial precursor cell marker XlFli and the
hematopoietic precursor cell marker SCL at the neurula, whereas embryos injected with morpholino antisense oligonucleotides for Xapelin and
Xmsr displayed attenuated expression of Tie2, α-globin, XPOX2, and cTnI, markers of endothelium, erythrocytes, myeloid cells, and
cardiomyocytes, respectively. XlFli morpholino had similar effects to Xapelin and Xmsr morpholinos on cardiac differentiation, suggesting an
unexpected potential relationship between the endothelium and cardiac differentiation. Forced expression of constitutive active Gαi rescued the
phenotypes of Xmsr morpholino-injected embryos, indicating that the i/o type of G protein α subunit acts downstream of Xmsr.
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Apelin is a newly identified peptide ligand for an orphan
receptor, APJ (Tatemoto et al., 1998). APJ was isolated as an
orphan G-protein-coupled receptor (GPCR) with sequence
similarity to the angiotensin receptor AT-1 (O'Dowd et al.,
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doi:10.1016/j.ydbio.2006.06.028precursor protein (preproapelin) and subsequently digested to
the active ligand (apelin). Transcripts and proteins of apelin
and APJ have been detected in both central nervous system
and peripheral tissues, including blood vessels and cardio-
myocytes (De Falco et al., 2002; Habata et al., 1999; Hosoya
et al., 2000; Kleinz and Davenport, 2004; Kleinz et al., 2005;
Tatemoto et al., 1998). Consistent with this pattern of
expression, apelin plays multiple roles in regulating cardio-
vascular function including lowering blood pressure and
increasing cardiac contractility (Szokodi et al., 2002;
Tatemoto et al., 2001). Despite these important physiological
functions, the roles of apelin and APJ in development are
unknown. Devic et al. showed that mouse APJ and Xenopus
mesenchyme-associated serpentine receptor (Xmsr), the Xe-
nopus homologue of APJ, are expressed in embryonic
endothelium, implying roles in vascular development (Devic
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recently shown to has angiogenic activity in adult mammals
(Kasai et al., 2004).
Vascular and hematopoietic cell lineages are close in
origin. Several reports suggest the existence of “hemangio-
blast”, bipotential progenitor cells that can differentiate into
both endothelium and blood cells (Jaffredo et al., 2000;
Mandal et al., 2004). Existence of the hemangioblast is
supported by the findings that loss of function or forced
expressions of several genes affects both types of cells. For
example, mouse embryos homozygous for Flk-1 lack both
vascular structures and expression of the hematopoietic
marker Gata-1 (Shalaby et al., 1995). Hematopoietic and
endothelial cells have also been shown to arise from a single
blast colony-forming cell derived from the embryoid body
(Choi et al., 1998). However, despite a substantial amount of
indirect evidence, hemangioblasts have not been isolated in
vivo and the mechanisms by which endothelial and hemato-
poietic precursors undergo initial specification or subsequent
separation remain unknown.
Cardiac precursor cells are first induced in the gastrula,
where they express markers such as the transcription factor
Nkx2.5 (Tonissen et al., 1994). However, the contractile
component of cardiac muscle is first expressed in the tailbud
stage, long after the first expression of primary transcription
factor, indicating the additional requirement of activating
factor(s) (Bruneau, 2002; Mohun et al., 2003; Zaffran and
Frasch, 2002). Cardiac and endothelial development has been
shown to be independent. Mice lacking genes necessary for
blood vessel formation show cardiac malformations as well as
blood vessel disruption in some of these reports (Dumont et
al., 1994; Sato et al., 1995); however, most of the cardiac
defects were modest and effected on the size or the function
of the heart, not on the differentiation, indicating that these
were secondary effects due to the insufficiency of coronary
arteries. Moreover, in the cloche mutant, cardiomyocytes
differentiate in the absence of almost all endothelium (Stainier
et al., 1995).
GPCRs transduce extracellular signals to downstream
trimeric G proteins, which consist of α, β, and γ subunits. G
protein α subunits (Gα) act in a wide variety of transduction
pathways and have been classified into 4 families based on their
structural similarities: Gαi/o, Gαs, Gαq/11, and Gα12/13
(Neves et al., 2002). Both Gαi/o family and the Gαq/11 family
have been suggested to act downstream of APJ, indicating that
the downstream Gα varies depending on the situation (Masri et
al., 2002; Szokodi et al., 2002).
In this study, we identified Xenopus laevis preproapelin
(Xpreproapelin) and investigated the roles of Xapelin and
Xmsr in cardiovascular development. Gain and loss of
Xapelin and Xmsr function affected the endothelial,
hematopoietic, and cardiac differentiation. We also examined
the loss of function of another endothelial gene, XlFli, which
led to the cardiac defects similar to those observed in
Xapelin- and Xmsr-depleted embryos. These results imply
the possible relationship between endothelial and cardiac
differentiation.Materials and methods
Constructs
Donated plasmids
pBluescript-Tie2 was kindly donated by Dr. M. Maeno (Iraha et al., 2002).
pGEM Teasy-α-globinT3 was kindly donated by Dr. K. Nagamine (Nagamine et
al., 2005). pcDNAIII Gαi2 Q205L, pcDNAIII Gαs short, pcDNAIII Gαq Q209L,
and pCEFL G12 QL were kind gifts of Dr. Gutkind.
Constructed plasmidsPlasmid
nameVector InsertpBluescript
II-XapelinpBluescript
IIPCR-product
Fw: CGGGATCCTGGATCTCCGCTTGCTTGTT
Rv: AGTGTGCAAAAGGGCTGTTApCS2-
XapelinpCS2 PCR-product
Fw: ATGAATCTCAGACTTTGGGCAC
Rv: TTAGAAGGGCATTGGGCCCTpCS2-
Xapelin
5mpCS2 PCR-product
Fw: CGGGATCCATGAACCTGAGGCTATG
GGCTCTGGC
Rv: TTAGAAGGGCATTGGGCCCTpCS2-
Xapelin-
mycpCS2-
mycPCR-product
Fw: CGGGATCCTGGATCTCCGCTTGCTTGTT
Rv: CGGAATTCGCGAAGGGCATTGGGCCCTTGTpCS2-
Xapelin
5m-mycpCS2-
mycPCR-product
Fw: CGGGATCCATGAACCTGAGGCTATGG
GCTCTGGC
Rv: CGGAATTCGCGAAGGGCATTGGGCCCTTGTpBluescript
II-XmsrpBluescript
IIPCR-product
Fw: CGGGATCCTCTGCTTCTGGGACAGGACT
Rv: CGGAATTCTCAGATTTTTGAGTCTGTGCACpCS2-
Xmsr
5mpCS2 PCR-product
Fw: CGGGATCCATGGAGACTGAGGGGTTAAGCC
Rv: CGGAATTCTCAGATTTTTGAGTCTGTGCACpCS2-
Xmsr-
mycpCS2-myc PCR-product
Fw: CGGGATCCTCTGCTTCTGGGACAGGACT
Rv: CGGAATTCGCGATTTTTGAGTCTGTGCACTpCS2-Xmsr
5m-mycpCS2-myc PCR-product
Fw: CGGGATCCATGGAGACTGAGGGGTTAAGCC
Rv: CGGAATTCGCGATTTTTGAGTCTGTGCACTpGEM-
XlFlipGEM-
TeasyPCR-product
Fw: CGGGATCCATGGACGGAACCATTAAGGA
Rv: CGGAATTCCTAGTAAAAACCACCTAAGTGGGpCS2-
XlFli
5mpCS2 PCR-product
Fw: CGGGATCCATGGATGGTACGATAAAAGA
Rv: CGGAATTCCTAGTAAAAACCACCTAAGTGGGpCS2-XlFli
5′ UTR-
HApCS2-HA PCR-product
Fw: CGGGATCCGTGTGGGAAGGTATCGG
Rv: CCATCGATGTAAAAACCACCTAAGTGGGpCS2-XlFli
5m-HApCS2-HA PCR-product
Fw: CGGGATCCATGGATGGTACGATAAAAGA
Rv: CCATCGATGTAAAAACCACCTAAGTGGGpBluescript
II-Nkx2.5pBluescript
IIPCR-product
Fw: GTGGATCCATGTTTGCCAGTCCTGTGACA
Rv: GGCCTCGAGCTACCAAGCTCGGATGCCATGpBluescript
II-XPOX2pBluescript
IIPCR-product
Fw: GGGGAAGTCTTATTCCAGGAAAC
Rv: GCCACAAAGTCTTCTATAGGCApBluescript
II-cTnIpBluescript
IIPCR-product
Fw: CTGATGAGGAAGAGGTAACC
Rv: CCTCACGTTCCATTTCTGCCpBluescript
II-SCLpBluescript
IIPCR-product
Fw: TTGCAGAGCCCCACTTACCC
Rv: GGCGCACCATCTAAAGAACTTCC(continued on next page)
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Gαi2QLpCS2 Digested from pcDNAIII Gαi2 Q205LpCS2-Gαs
shortpCS2 Digested from pcDNAIII Gαs shortpCS2-
GαqQLpCS2 Digested from pcDNAIII Gαq Q209LpCS2-
Gα12QLpCS2 Digested from pCEFL G12QLEmbryo manipulation
Embryos were obtained and cultured as described previously (Inui and
Asashima, 2004) and were staged according to Nieuwkoop and Faber (1967).
Reverse transcriptase-polymerase chain reaction (RT-PCR) and rapid
amplification of cDNA ends (RACE)
Total RNA from embryos was extracted using Isogen (Nippon Gene, Tokyo,
Japan). cDNA was synthesized using SuperScriptII (Invitrogen, Carlsbad, CA,
USA). PCR was performed using ExTaq DNA polymerase (TaKaRa, Kyoto,
Japan). Each experiment was performed according to the manufacturers'
instructions. The primers used were: Xapelin upper: 5′-ATGAATCTCA-
GACTTTGGGCAC-3′ Xapelin lower: 5′-TTAGAAGGGCATTGGGCCCT-3′
Xmsr upper: 5′-GGAAGGTCATCTGCTGATTAC-3′ Xmsr lower: 5′-
GTCCAACCAGCTCTCCTGTT-3′ ODC upper: 5′-GTCAATGATGGAGTG-
TATGGATC-3′ ODC lower: 5′-TCCATTCCGCTCTCCTGAGCAC-3′. 5′
RACE was performed using FirstChoise RLM-RACE KIT (Ambion, Austin,
TX, USA) according to the manufacturer's instructions. Xapelin+622 5′-AGTG-
TGCAAAAGGGCTGTTA-3′ and Xapelin stop 5′-TTAGAAGGGCATT-
GGGCCCT-3′ were used as the outer and inner RACE primers, respectively.
Morpholino antisense oligonucleotides, RNA synthesis, and
microinjection
Morpholino antisense oligonucleotides (MOs) were designed to anneal with
the mRNA sequences around the first methionine of Xapelin, Xmsr, and XlFli:
(XapelinMO: 5′-CAAGCGAGCAGAGCTGTGCTGAATC-3′, XmsrMO: 5′-
CTTTGAAGGCTGTGTGTGGAAGCAATA-3′, XlFliMO: 5′-TCCT-
TAATGGTTCCGTCCATGTGTC-3′) (Gene Tools LLC, Oregon, USA).
Standard controlMO was purchased from Gene Tools LLC: (ControlMO 5′-
CCTCTTACCTCAGTTACAATTTATA-3′).
Plasmids were linearized with NotI to prepare templates, and mRNAs were
transcribed using the mMESSAGE mMACHINE SP6 kit (Ambion, Austin, TX,
USA).
mRNA, MO, and plasmid DNA were microinjected bilaterally into the
dorsal vegetal hemispheres of 8-cell stage embryos, unilaterally into the lateral
marginal zone of 4-cell stage embryos, or into the animal pole region of 2-cell
stage embryos.
Western blotting
Western blotting was performed essentially as described previously (Inui
and Asashima, 2004). Anti-c-myc antibody (9E10, Santa Cruz Biotechnology,
Santa Cruz, CA, USA) and anti-HA antibody (Y-11, Santa Cruz Biotechnology)
were used to recognize tagged proteins.
Histology
Embryos were fixed with Bouin's fluid, dehydrated through a graded
ethanol series, infiltrated in lemozol, and embedded in Histprep (Wako Pure
Chemical Industries, Osaka, Japan). The tissues were sectioned at 8 μm and
stained with hematoxylin and eosin.
Whole-mount in situ hybridization
Whole-mount in situ hybridization was performed essentially according to
Harland (1991), with the following modifications. When mRNA or MO-injectedembryos were used, breaching with 7% H2O2, 13% H2O, and 80% methanol
was performed prior to the hybridization. In these cases, the protease K
treatment, acetylation, and second fixation procedure were omitted.Results
Isolation of Xenopus apelin
We initially identified a X. laevis EST (GenBank accession
no. TC129878) in the NCBI database encoding a partial mRNA
sequence similar to human preproapelin (GenBank accession
no. AB023493). 5′ RACE was performed using cDNA from
stage 42 embryos to determine the open reading frame (ORF)
sequence of Xenopus preproapelin. Xpreproapelin cDNA
encoded a putative protein of 76 amino acid residues that had
50%, 53%, 53%, and 55% identity with chick, bovine, mouse,
and human preproapelin, respectively (Fig. 1). In mammals,
preproapelin post-translationally digested to several different C-
terminal apelin fragments, ranging from 13 to 36 amino acids in
length; all have been reported to have ligand activity and are
present in vivo. Interestingly, the C-terminal-most 12 amino
acid residues of Xpreproapelin were fully conserved among
species, suggesting functional importance of this region.
Expression pattern of Xpreproapelin mRNA in developing
embryos
Xpreproapelin mRNA expression was investigated by RT-
PCR and whole-mount in situ hybridization and compared to
the expression pattern of Xmsr mRNA, the putative receptor of
Xapelin. Xpreproapelin mRNA existed maternally and
increased after the blastula stage (Fig. 2A), coincident with
the onset of Xmsr mRNA expression (Devic et al., 1996).
During the gastrula stage, Xpreproapelin mRNA expression
was restricted to the marginal zone bilateral to the dorsal lip
(Figs. 2B, C, arrowheads), whereas Xmsr mRNAwas expressed
throughout the marginal zone except for the dorsal marginal
zone (Figs. 2F, G, arrowheads). This Xmsr expression pattern is
thought to encompass the regions from which progenitors of
cardiac, endothelial, and hematopoietic cells arise. At the
neurula stage (stage 18), Xpreproapelin mRNA was detected
in the anterior ventral region of the embryo (Figs. 2D, E,
arrowheads). XmsrmRNAwas also detected in this region at the
neurula (Figs. 2H, I, arrowheads). By the early tailbud stage
(stage 22), Xpreproapelin mRNA was localized in the anterior
ventral region (Figs. 2J, K), dorsal midline (Fig. 2L), and
posterior part (Fig. 2J) of the embryo. This expression pattern
was consistent with the observed and reported localization of
Xmsr transcripts at the same stage (Figs. 2M–O and Devic et
al., 1996). At the tailbud stage (stage 30), XpreproapelinmRNA
was localized in a more restricted region related to the vascular
tissues; this was presumed to be the anterior and posterior
cardinal veins, aortic arcs, and dorsal longitudinal anastomosing
vessel (vessel nomenclature are according to Levine et al., 2003)
(Figs. 2P–R). Xmsr transcripts were expressed in the endothe-
lium of major blood vessels such as anterior and posterior
cardinal veins, aortic arcs, endocardium, and vascular vitelline
Fig. 1. Comparison of the amino acid sequences of preproapelin from different species. The red box indicates the 12 C-terminal amino acids. Conserved amino acid
residues are indicated by the asterisks, and similar amino acid residues are indicated by the dots. Gaps are introduced into the sequences to optimize the sequence
homologies, as indicated by the bars.
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cardiovascular-related regions, Xpreproapelin transcript was
also observed in the notochord, neural tube, and tailbud (Figs.
2P, Q). These results showed that the Xpreproapelin is expressed
temporally and spatially within or adjacent to the sites of Xmsr
expression; the pattern is broad in early stages and confine to the
tissues related to developing cardiovasculature.
The expressions of Xpreproapelin and Xmsr mRNA at stage
22 also partially overlapped with, or were in adjacent to,
expression of the precardiac marker Nkx2.5, which was
expressed in mesodermal and endodermal cells in the anterior
ventral region of stage 22 embryos (Figs. 3A, D). Xpreproa-
pelin transcripts were detected in the endodermal layer of this
region (Figs. 3B, E), while Xmsr transcripts were detected in the
mesodermal layer (Figs. 3C, F).
Overexpression of Xpreproapelin affects endothelial and
hematopoietic precursor cells and cardiac morphogenesis
To investigate the effect of Xapelin overexpression in develop-
ing embryos, synthesized Xpreproapelin mRNAwas injected into
the dorsal vegetal hemisphere of 8-cell stage embryos, which were
examined at the tadpole stage (stage 45). By this stage, the heart has
formed into a looped tube with separated chambers, beating in
steady rhythm (Fig. 4A, arrowhead). The Xpreproapelin mRNA-
injected embryos exhibited edema and generated tubular hearts
with no evidence of looping or chamber separation (Fig. 4C,
arrowhead). Beating was attenuated or completely absent in some
embryos. Sectioning of these embryos revealed a thin heart and
poor separation of atria and ventricle compared to control
noninjected embryos (Figs. 4B, D, arrowhead). The edema
phenotype was Xpreproapelin mRNA dose-dependent (Fig. 4E).
Next, we examined the expression of several marker genes in
the Xpreproapelin mRNA-injected embryos to investigate the
effects on cardiovascular development. At the neurula stage, the
expression domains of XlFli, an endothelial precursor cell
marker (Fig. 4K), and SCL, a hematopoietic precursor cell
marker (Fig. 4L), were expanded laterally in Xpreproapelin-
overexpressing embryos compared to control embryo (Figs. 4F,
G). RT-PCR analysis suggested that the absolute amounts of
mRNAs were not increased in Xpreproapelin-overexpressing
embryos (data not shown), indicating the effect on thedistribution of the precursor cells, but not on the number of
mRNA-expressing cells. In contrast, expression of Nkx2.5, a
precardiac cell marker, was unaffected by overexpression of the
Xpreproapelin mRNA (Figs. 4H, M), which was somewhat
inconsistent with the abnormal heart morphology observed at
the tadpole stage. We therefore examined the expression of
cardiac differentiation markers in Xpreproapelin-overexpres-
sing embryos at the tailbud stage. In control embryos, cardiac
troponin I (cTnI), a contractile component of beating heart, was
expressed in two patches linked in the ventral midline (Fig. 4I).
In the Xpreproapelin mRNA-injected embryos, however, cTnI
expression patches were separate in each side (Fig. 4N).
Transverse sections through the heart region of the embryos
showed that the right and left heart primordia of the Xpre-
proapelin mRNA-injected embryos were separate (Fig. 4O,
arrowheads), whereas the normal heart primordia had fused and
formed a tubular structure (Fig. 4J, arrowhead). As seen in Fig.
4D, the heart primordia of Xpreproapelin-overexpressing
embryo fused at the later in development, suggesting that
fusion of the heart primordia was retarded rather than blocked.
Taken together, these results show that overexpression of
Xpreproapelin disorganized the distribution of endothelial and
hematopoietic precursor cells and cardiomyocytes in the
embryos, resulting in an edema phenotype.
Xapelin and Xmsr knocked down embryos displayed abnormal
cardiovascular system
We used the morpholino antisense oligonucleotide (MO)
approach to clarify the role of endogenous Xapelin and Xmsr in
developing embryos. MOs were designed against the 5′ UTR
sequences of Xpreproapelin mRNA (XapelinMO) and Xmsr
mRNA (XmsrMO). The target sequence specificity of the oligos
was confirmed by western blot analysis, using myc-tagged
constructs (Figs. 5A, B). MOs blocked the translation from the
mRNAwith their target sequence (Xapelin-myc and Xmsr-myc,
respectively) (Figs. 5A, B, lane 2), but not from mRNAs lacking
the target sequences (Xapelin 5m-myc and Xmsr 5m-myc) (Figs.
5A, B, lane 4). It is interesting to note that tagged proteins of
different molecular sizes were found in the Xapelin-mycmRNA-
injected embryos, suggesting that digestion occurred post-
translationally.
Fig. 2. Expression patterns of Xpreproapelin and Xmsr mRNA. (A) RT-PCR analysis of Xpreproapelin and Xmsr mRNA during development. Ornithine
decarboxylase (ODC) was used as an internal control. (B, C) Expression of Xpreproapelin mRNA at stage 10. Xpreproapelin mRNAwas detected in the marginal
zone, at the bilateral area of the dorsal lip (arrowheads). Inset in panel B shows a magnified view of the expression. (D, E) Expression of XpreproapelinmRNA at stage
18, in the anterior ventral region of the embryo (arrowheads). (F, G) Expression of Xmsr mRNA at stage 10, in the marginal zone except for dorsal marginal zone
(arrowheads). (H, I) Expression of Xmsr mRNA at stage 18, in the anterior ventral region of the embryo (arrowheads). (J–L) Expression of Xpreproapelin mRNA at
stage 22, in regions lateral and posterior to the cement gland (CG), the dorsal posterior part of the embryo, and the dorsal midline. (M–O) Expression of Xmsr mRNA
at stage 22, in areas lateral and posterior to the cement gland (CG), the dorsal posterior part of the embryo, and the dorsal midline. (P–R) Expression of Xpreproapelin
mRNA at stage 30, around the anterior and posterior cardinal vein (ACV white arrowhead, PCV black arrowhead), aortic arcs (AA, arrowhead), dorsal longitudinal
anastomosing vessel (DLAV, arrowhead), notochord (NC), neural tube (NT), and tailbud. (S–U) Expression of Xmsr mRNA at stage 30, in the anterior and posterior
cardinal vein (ACV white arrowhead, PCV black arrowheads), aortic arcs (AA, arrowheads), endocardium (EC arrowhead), vascular vitelline network (VVN
arrowhead), and tailbud. B, F, L, O: dorsal view;, C, G: vegetal view, dorsal upward, D H; anterior view, E, I, K, N, R, U: ventral view, J, M, P, Q, S, T: lateral view.
Panels Q and T are magnified views of the dorsal part of the cleared embryos shown in panels P and S, respectively.
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Fig. 3. Comparison of expression patterns of Xpreproapelin, Xmsr, and Nkx2.5
mRNA. (A, D) Expression of Nkx2.5mRNA at stage 22, in the mesodermal and
endodermal layers of the anterior ventral region. (B, E) Expression of Xpre-
proapelinmRNA in stage 22, in the endodermal layer of anterior ventral region.
(C, F) Expression of Xmsr mRNA in stage 22 embryo, in the mesodermal layer
of the anterior ventral region. Cement glands are indicated by the dotted line in
panels A–C. en: endodermal layer, mes: mesodermal layer, Scale bar: 100 μm.
Fig. 4. Overexpression of Xpreproapelin. (A) Control embryo at stage 45. The positio
of control embryo at stage 45, showing separate atria (a) and ventricle (v) and promin
stage 45, showing edema and abnormal heart morphology (arrowhead). (D) Section of
had thin walls and poor chamber separation (arrowhead). (E) Graph showing the fre
Xpreproapelin mRNA (Ap mRNA) or 1000 pg of beta-galactosidase mRNA (Beta-g
obtained. The graph shows the representative result of one experiment. (F–H) Expres
of cTnI in the control embryo at stage 30. (J) Section through the heart region of
Expression of XlFli, SCL, and Nkx2.5 at stage 17 in the Xpreproapelin mRNA (1 ng)
at stage 30. (O) Section through the heart region of the Xpreproapelin-injected emb
panels I and N indicates the level of the sections shown in panels J and O. Scale ba
193M. Inui et al. / Developmental Biology 298 (2006) 188–200XapelinMO and XmsrMOwere injected into two dorsal vegetal
hemispheres of 8-cell stage embryos, whichwere examined at stage
45. The XapelinMO-injected embryos and XmsrMO-injected
embryos exhibited similar phenotypes: severe edema, abnormal
heart morphology, and attenuated heartbeat and blood flow. The
heart of XapelinMO- and XmsrMO-injected embryos appeared as
thin tubes (Figs. 5E, H) compared to that of controlMO-injected
embryos (Fig. 5C). Sectioning of XapelinMO- and XmsrMO-
injected embryos revealed shrunken hearts containing no trabeculae
in an expanded pericardiac cavity (Figs. 5F, I, arrowhead), whereas
the heart of the controlMO-injected embryo contained prominent
trabeculae and separate atria and ventricle (Fig. 5D, arrowhead).
Pharynx was also distorted in the XapelinMO- and XmsrMO-
injected embryos, suggesting that these genes also play some role in
endodermdevelopment. The phenotypeswereMOdose-dependent
and partially rescued by coinjecting plasmid DNAs encoding the
ORFs of Xpreproapelin or Xmsr containing 5 silent mutations
(pCS2-Xapelin 5m and pCS2-Xmsr 5m, respectively) (Figs. 5G, J–
L). Moreover, coinjection of low doses of XapelinMO and
XmsrMO, each of which had little effect alone, had significant
effect on the embryos (Fig. 5M). This synergistic effect indicatesn of heart is indicated by an arrowhead. (B) The section through the heart region
ent trabeculae (arrowhead). (C) Xpreproapelin mRNA (1 ng)-injected embryo at
heart region of the XpreproapelinmRNA-injected embryo at stage 45. The heart
quencies of edematous embryos with 125 pg, 250 pg, 500 pg, and 1000 pg of
al)-injected. Three independent experiments were performed and similar results
sion of XlFli, SCL, and Nkx2.5 at stage 17 in the control embryos. (I) Expression
control embryo at stage 30 showing a single heart tube (arrowhead). (K–M)
-injected embryo. (N) Expression of cTnI in the Xpreproapelin-injected embryo
ryo at stage 30, showing a separated heart tube (arrowheads). The black line in
r: 100 μm.
Fig. 5. Xapelin and Xmsr knocked down embryos exhibited abnormal cardiovascular systems. (A, B) Western blotting assessing the specificities of XapelinMO and
XmsrMO. XapelinMO (40 ng) and XmsrMO (20 ng) inhibited translation of mRNAs with 5′ UTR sequences (250 pg) (lane 2), but not from mRNAs that lack the 5′
UTR sequences (250 pg) (lane 4). (C, E, H) ControlMO (40 g)-, XapelinMO (40 ng)-, and XmsrMO (20 ng)-injected embryo at stage 45. (D, F, I) Section of the heart
region of controlMO-, XapelinMO-, and XmsrMO-injected embryo at stage 45. Arrowheads indicate the position of the heart. (G, J) Embryos coinjected plasmid DNA
(10 pg of pCS2-Xapelin 5m and 50 pg of pCS2-Xmsr 5m, respectively) with MOs (40 ng of XapelinMO and 20 ng of XmsrMO, respectively). (K, L, M) Graphs of the
frequencies of edematous embryos in MO- and DNA-injected embryos. Three independent experiments were performed and showed similar results. The graphs show
the representative results of one experiment. aMO: XapelinMO, mMO: XmsrMO, cMO: controlMO, Scale bar: 100 μm.
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consistent with their ligand–receptor relationship.
Xapelin and Xmsr are required for endothelium differentiation
Since Xpreproapelin and Xmsr are expressed in regions
around the vascular tissue, we examined the effect of
XapelinMO and XmsrMO on an expression of a marker gene
of endothelial differentiation. XapelinMO and XmsrMO were
injected unilaterally into the lateral marginal zone of 4-cell stage
embryos, and expression of endothelial gene Ami was examined
at the tailbud stage. Ami was expressed in the posterior cardinal
vein, intersomitic veins, and vascular vitelline network at this
stage (Fig. 6A, arrows and Inui and Asashima, 2006). The
expression of Ami was attenuated in XapelinMO- and
XmsrMO-injected sides of the embryos (Figs. 6D, F) compared
to the uninjected sides (Figs. 6C, E). The expression was not
affected by controlMO injection (Figs. 6A, B). These resultssuggest that Xapelin and Xmsr are required for endothelial
differentiation and/or formation of the vascular network.
Xapelin and Xmsr are required for expression of
cardiovascular genes
Expressions of endothelial, hematopoietic, and cardiac
marker genes in the anterior ventral region of XapelinMO- and
XmsrMO-injected embryos were next examined to evaluate the
role of Xapelin and Xmsr in cardiovascular development of 8-
cell stage embryos. MOs were injected into two dorsal vegetal
hemispheres. At the neurula stage, injection of XapelinMO or
XmsrMO attenuated the expression of XlFli (Figs. 7D, G and
Table 1) and SCL (Figs. 7E, H and Table 1) compared with the
injection of controlMO (Figs. 7A, B and Table 1), whereas
Nkx2.5 expression was the same as in the controlMO-injected
embryos (Figs. 7C, F, I and Table 1). At the tailbud stage, the
endothelium marker gene Tie2 was expressed in the
Fig. 6. Xapelin and Xmsr are required for the expression of endothelial marker gene. (A, B) Expression of Ami in the controlMO (40 ng)-injected embryo at stage 35, in
the posterior cardinal vein (PCVarrowhead), intersomitic veins (ISV arrowhead), and vascular vitelline network (VVN, arrowhead). (C, D) Expression of Ami in the
XapelinMO (40 ng)-injected embryo. (E, F) Expression of Ami in the XmsrMO (20 ng)-injected embryo.
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erythrocyte marker α-globin was expressed in the ventral blood
island (Fig. 7K), while the myeloid marker XPOX2 was
expressed in migrating phagocytes as scattered dots in a wide
area of the embryo (Fig. 7L). cTnI and Nkx2.5were expressed in
myocardium (Figs. 7M, N). Expression of Tie2 (Figs. 7O, T and
Table 1), α-globin (Figs. 7P, U and Table 1), XPOX2 (Figs. 7Q,
V and Table 1), and cTnI (Figs. 7R, W and Table 1) was
attenuated in XapelinMO- and XmsrMO-injected embryos.
Expression of other cardiac differentiation markers such as
myosin heavy chain α (MHCα) andmyosin light chain 2 (MLC2)
was also attenuated (Supplementary Fig. 1, Table 1). In the heart
of controlMO-injected embryos, the myocardial layer (Fig. 7a,
arrowhead) formed the tube or trough, enfolding the endocardial
tube (Fig. 7a, arrow), whereas no tube or trough structure was
observed in the XapelinMO- and XmsrMO-injected embryos,
even though a mesodermal layer was present (Figs. 7b, c).
Despite the abnormal morphology, expression of Nkx2.5 in the
XapelinMO- and XmsrMO-injected embryos was unaffected
(Figs. 7S, X) compared with controlMO-injected embryo (Fig.
7N) at the tailbud stage, suggesting that the cardiac character-
istics of precardiac cells had not been completely lost. Overall,
these results indicate that Xapelin and Xmsr are required for
endothelial and hematopoietic precursor specification and for
the differentiation of endothelium, erythroid cells, myeloid cells,
and cardiomyocytes.
The XlFli-depleted embryos exhibit phenotypes similar to that
of the Xapelin- and Xmsr-depleted embryos
Xapelin and Xmsr are not expressed in cardiomyocytes,
erythrocytes, or myeloid cells at the tailbud stage, so we next
assessed whether the effects observed thus far were cell-autonomous. The effect of Xmsr depletion on hematopoietic
and cardiac differentiation could be either cell-autonomous
effect through the broad expression observed at early stages of
development or via non cell-autonomous effects through the
primary effect on endothelium precursors. To address this
option, we performed loss of function analyses of XlFli, a
transcription factor expressed in endothelial precursor cells,
whose expression was attenuated by XapelinMO and XmsrMO
(Figs. 7D, G). We designed an MO for XlFli (XlFliMO) and
examined its effect on cardiovascular development. The target
sequence specificity of XlFliMO was confirmed by using
mRNAs of tagged proteins and western blot analysis showing
that XlFliMO specifically inhibited the translation of mRNA
that had its target sequence (Fig. 8A). XlFliMO-injected
embryos were phenotypically similar to the Xapelin- and
Xmsr-depleted embryos; at stage 45, the XlFliMO-injected
embryos exhibited severe edema, abnormal heart morphology,
a weak heartbeat, and lack of circulating erythrocytes,
compared to the controlMO-injected embryos (Figs. 8B, C).
These phenotypes were partially rescued by coinjecting the
expression plasmid of XlFli, which had 5 silent mutations
around the first methionine (pCS2-XlFi 5m) (Figs. 8D, E).
Marker gene expression in the XlFliMO-injected embryos was
also comparable to those in the Xapelin- and Xmsr-depleted
embryos in that expression of SCL was attenuated and
expression of Nkx2.5 was unaffected compared with the
controlMO-injected embryos at the neurula stage (Figs. 8G,
H, L, M). By the tailbud stage, Tie2, α-globin, cTnI, MHCα,
and MLC2 expression was attenuated by the XlFliMO injection
compared to the controlMO-injected embryos (Figs. 8I–K, N–
P and data not shown). These results indicate that XlFli is
required for differentiation of endothelium, erythrocytes, and
cardiomyocytes. Simultaneous injection of ineffectively low
Fig. 7. Xapelin and Xmsr are required for the expression of cardiovascular genes. (A–C) Expressions of XlFli, SCL, and Nkx2.5 in the controlMO (40 ng)-injected
embryos at stage 17. (D–F) Expressions of XlFli, SCL, and Nkx2.5 in the XapelinMO (40 ng)-injected embryos at stage 17. (G–I) Expressions of XlFli, SCL, and
Nkx2.5 in the XmsrMO (20 ng)-injected embryos at stage 17. (J–N) Expressions of Tie2, α-globin, XPOX2, cTnI, and Nkx2.5 in the controlMO-injected embryos.
(O–S) Expressions of Tie2, α-globin, XPOX2, cTnI, and Nkx2.5 in the XapelinMO-injected embryos. (T–X) Expressions of Tie2, α-globin, XPOX2, cTnI, and
Nkx2.5 in the XmsrMO-injected embryos. (a–c) Section through the heart region of controlMO-, XapelinMO-, and XmsrMO-injected embryos at stage 30. The
black line in panels N, S, and X indicates the level of the sections shown in panels a–c. Arrow: endocardium. Arrowhead: myocardium, Scale bar: 100 μm.
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phenotype (Fig. 8F), functionally aligning XlFli with Xapelin
and Xmsr in cardiovascular development.
Gαi/o acts downstream of Xmsr
To identify the downstream mediator of Xmsr in Xenopus
development, we performed a rescue experiment using wild-
type or constitutively active form of Gα. RT-PCR and whole-
mount in situ hybridization revealed that at least one memberof each of the four Gα subunit families (Gαi/o, Gαs, Gαq/11,
and Gα12/13) was expressed in Xenopus embryos at the early
tailbud (Supplementary Fig. 2). Constitutively active or
wildtype forms representing the four mammalian Gα subunit
types were coinjected with XmsrMO to the dorsal vegetal
hemispheres of 8-cell stage embryos. Gαi2QL (i/o type),
GαqQL (q/11 type), and Gα12QL (12/13 type) were the
constitutively active forms, and Gαs short (s type) was the
wildtype form. XmsrMO induced the edema phenotype in
100% of injected embryos, which was not seen in any of the
Table 1
Summary of effects of Xapelin MO and Xmsr MO
MO XlFli SCL Nkx2.5
(stage 17)
cTnI MHCα
cMO 0% (0/24) 0% (0/27) 0% (0/36) 0% (0/27) 0% (0/22)
aMO 65% (15/23) 80% (20/25) 3% (1/34) 36% (10/28) 27% (9/33)
mMO 56% (14/25) 88% (23/26) 0% (0/33) 74% (20/27) 62% (21/32)
MO MLC2 Tie2 α-Globin XPOX2
cMO 3% (1/30) 4% (1/24) 8% (2/24) 0% (0/22)
aMO 26% (8/31) 61% (17/28) 46% (13/28) 48% (12/25)
mMO 59% (22/37) 61% (20/33) 75% (18/24) 72% (18/25)
The proportions of embryos with attenuated expression are shown as
percentages. Numbers of embryos are shown in parentheses. cMO: controlMO,
aMO: XapelinMO, mMO: XmsrMO.
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pCS2-Xmsr 5m plasmid DNA rescued the edema phenotype
in 55% of the embryos (Figs. 9C, P), whereas coinjection of
pCS2-EGFP had no effect on the defect (Figs. 9D, P),
demonstrating the specificity of the rescue activity. Coinjection
of pCS2-Gαi2QL (Figs. 9E, P), pCS2-Gαs short (Figs. 9F, P),
pCS2-GαqQL (Figs. 9G, P), and pCS2-G12QL (Figs. 9H, P)
with XmsrMO rescued the phenotype in 53%, 32%, 25%, and
25% of the embryos, respectively, thus only pCS2-Gai2QL
displayed rescue activity comparable to that of pCS2-Xmsr 5m
(Figs. 9C, E, P). A similar tendency was observed for cTnI
mRNA expression; it was reduced in 82% of the XmsrMO-
injected embryos but not in any of the controlMO-injected
embryos (Figs. 9I, J, Q), and the reduction was rescued by
coinjection of pCS2-Xmsr 5m in 50% of the embryos (Figs.
9K, Q). Coinjection of pCS2-Gai2QL (Figs. 9L, Q), but not
pCS2-Gαs short, pCS2-GαqQL, or pCS2-G12QL (Figs. 9M–
O, Q), also efficiently rescued the reduced expression of cTnI
mRNA. These results indicate that the i/o type of Gα mediates
signal transduction downstream of Xapelin-Xmsr in Xenopus
cardiomyocyte differentiation.
Discussion
The expression pattern of Xpreproapelin and Xmsr mRNA
Where and when do Xapelin and Xmsr participate in
cardiovascular development? The expression of Xmsr transcript
was broad at early embryonic stages yet confined to cells of the
endothelial lineage in later stages. Xpreproapelin mRNA was
expressed in the vicinity of Xmsr expression, potentially
facilitating interaction between the secreted Xapelin peptide
and Xmsr (Figs. 2, 3). Xmsr mRNA is expressed in most of the
marginal zone at the gastrula stage (Fig. 2), preceding the
earliest expression of endothelial and hematopoietic and cardiac
marker genes. This provides the temporal and spatial potential
for Xapelin and Xmsr to affect endothelial, hematopoietic, and
cardiac differentiation cell autonomously. However, our loss of
function results might suggest non-cell autonomous action of
these genes on cardiac and hematopoietic differentiation
(discussed below).Overexpression of Xapelin affects the distribution of
cardiovascular tissues
Overexpression of Xapelin influenced the distribution of
endothelial and hematopoietic precursor cells and cardiomyo-
cytes. Not much is known about the distribution of endothelial
and hematopoietic precursor cells in X. laevis, on the other
hand, phenotype of separate heart primordia (cardia bifida) is
reported to be caused by defects in cardiac differentiation,
endoderm differentiation, extracellular matrix deposition, or
migration of heart primordia (Dickmeis et al., 2001; Reiter et
al., 2001; Saga et al., 1999; Trinh and Stainier, 2004). Kasai et
al. recently reported that apelin has chemoattractant activity for
retinal endothelial cells expressing APJ (Kasai et al., 2004),
thus our results might be the outcome of a migrating defect in
the precursor cells. Smith et al. showed that migrating myeloid
cells expressing XPOX2 transiently bisect the bilateral heart
primordia shortly before they fuse and form the tube structure,
indicating that myeloid cells have some role in cardiac
morphogenesis (Smith et al., 2002). We observed that Xapelin
and Xmsr affected XPOX2 expression (Figs. 7L, Q, V),
implying the alternative possibility that Xapelin and Xmsr
affected the heart morphology via an effect on myeloid cells.
Xapelin, Xmsr, and XlFli are required for the differentiation of
cardiovascular tissues
Loss of function of Xapelin and Xmsr disturbed endothelial,
hematopoietic, and cardiac differentiation. The question then arises
as towhich step doXapelin andXmsr affect these processes? Based
on the hypothesis that the hemangioblasts exist, our results, which
both endothelial and hematopoietic precursor cell marker are
affected byXapelin andXmsr depletion (Fig. 3), imply that Xapelin
and Xmsr might play some role in differentiating and/or
proliferating the hemangioblasts. Alternatively, Xapelin and Xmsr
may act after the endothelial and hematopoietic lineages have
separated for there specification.
The unaltered expression of Nkx2.5 and significant decrease in
terminal cardiac markers in the Xapelin- and Xmsr-depleted
embryos led us to suspect that these factors act in cardiac
differentiation between the primary transcription factors and the
terminal contractile components. The finding that loss of XlFli
affected cardiac differentiation presented an intriguing possibility
about the relationship between endothelial and cardiac differentia-
tion. Since XlFli is a transcription factor, the primary effect of loss
of XlFli would be restricted to the endothelial precursor cells.
Therefore, our results suggested the existence of an indirect, non-
cell-autonomous interaction between endothelial precursor cells
and cardiac differentiation. Attenuated expression of XlFli in
XmsrMO-injected embryos and the synergistic effect of XmsrMO
and XlFliMO suggested that the effect of loss of Xmsr on cardiac
differentiation could also be indirect effect from the endothelial
precursor cells (Figs. 7, 8). Together, our results imply an interaction
between endothelial differentiation and cardiac differentiation,
which is affected by the loss of Xapelin, Xmsr, and XlFli.
There have been a number of studies showing loss of function
of genes required for endothelial cell development, including a
Fig. 8. XlFli-depleted embryos displayed phenotypes similar to Xapelin- and Xmsr-depleted embryos. (A) Western blotting assessing the target sequence specificity of
XlFliMO. XlFliMO (20 ng) inhibited translation of injected mRNA with its target sequence (lane 4), but not of mRNA with 5 silent mutations around the first
methionine (lane 2). (B) ControlMO (20 ng)-injected embryo at stage 45. (C) XlFliMO (20 ng)-injected embryo at stage 45. (D) Embryos coinjected pCS2-XlFli 5m
(20 pg) with XlFliMO (20 ng). (E–F) Graphs showing the frequencies of edematous embryos in MO- and/or DNA-injected embryos. Three independent experiments
were performed and showed similar results. The graph shows the representative result of one experiment. (G–K) Expression of SCL, Nkx2.5, Tie2, α-globin, and cTnI
in the controlMO-injected embryos. (L–P) Expressions of SCL, Nkx2.5, Tie2, α-globin, and cTnI in the XlFliMO-injected embryos.
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but none reported as drastic a decrease in cardiac tissues in the
absence of endothelium as that reported here (Shalaby et al.,
1995; Stainier et al., 1995). Since the loss of Xapelin, Xmsr, and
XlFli also affected various types of cells, such as erythrocytes
and myeloid cells, which differentiate mutually interdepen-
dently, we cannot determine the direct association between
endothelial and cardiac differentiation. The relationships bet-
ween our results and the findings in other studies should there-
fore be considered carefully in further research.
APJ null mice exhibit insensitivity to the administration of
apelin in adults but are viable and essentially develop normally
(Ishida et al., 2004). The reason for the discrepancy between our
results and the findings in the APJ null mice is unknown, but
functionally redundant GPCRs and/or ligands may be present in
developing mouse embryos.Gαi/o as a downstream mediator of Xapelin and Xmsr
Several studies have shown that the activities of apelin are
sensitive to pertussis toxin (PTX), a specific inhibitor of Gαi/o
activation, implicating Gαi/o in apelin signaling pathway
(Hosoya et al., 2000; Masri et al., 2002). On the other hand,
Szokodi et al. showed PTX-insensitive apelin activity likely to
be independent of Gαi/o (Szokodi et al., 2002). In this case,
the activity was PLC- and PKC-dependent, suggesting that
Gαq/11, instead of Gαi/o, are the subunits involved down-
stream of apelin-APJ (Szokodi et al., 2002). Our results
indicate that Gαi/o, rather than Gαq/11, acts downstream of
apelin, at least in Xenopus cardiomyocyte differentiation (Fig.
9). Physiological role of G protein signaling is well
established, yet little is known about the function of trimeric
G proteins in cardiovascular development. On the basis of our
Fig. 9. Gαi/o acts downstream of Xmsr. (A) ControlMO (20 ng)-injected embryo at stage 45. (B) XmsrMO (mMO) (20 ng)-injected embryo at stage 45. (C–H)
Embryos coinjected pCS2-Xmsr 5m DNA (50 pg) (C), pCS2-EGFP DNA (50 pg) (D), pCS2-Gαi2QL (10 pg) (E), pCS2-Gαs short (10 pg) (F), pCS2-GαqQL (10 pg)
(G), and pCS2-Gα12QL (10 pg) (H) with XmsrMO at stage 45. The embryos shown in the left of panels C and E–H are the embryos with normal phenotypes and the
embryos shown in right of the panels are the embryos with edema phenotypes. The numbers shown in the bottom right of panels A–H indicate the percentage of
edematous embryos, and the numbers shown in the bottom left of the panels indicate the percentage of normal embryos. (I) cTnI expression in controlMO (20 ng)-
injected embryo. (J) cTnI expression in XmsrMO (mMO) (20 ng)-injected embryo. (K–O) cTnI expression in embryos coinjected with pCS2-Xmsr 5m DNA (50 pg)
(K), pCS2-Gαi2QL (10 pg) (L), pCS2-Gαs short (10 pg) (M), pCS2-GαqQL (10 pg) (N), and pCS2-Gα12QL (10 pg) (O) with XmsrMO. The embryos shown in the
left of panels J–M are the embryos with normal cTnI expression, and the embryos shown in the right of the panels are the embryos with reduced cTnI expression. The
numbers shown at the bottom right of panels I–O indicate the percentage of the embryos with reduced cTnI expression, and the numbers shown at the bottom left of the
panels indicate the percentage of the embryos with normal cTnI expression. (P, Q) Graphs summarizing the results above.
199M. Inui et al. / Developmental Biology 298 (2006) 188–200result, further investigation is necessary to shed light on the
precise mechanism by which G protein signal transduction re-
gulates this process.
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